Verastem, Inc. Equity-NMS: VSTM

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$8.63

Open :

$8.63

Today's high :

$9.4

Today's low :

$8.55

52W low :

$2.34

52W high :

$9.4

EPS(TTM): :

-3.5

Shares O/S :

61.55 M

Market cap :

558.83 M

What is the share price of Verastem, Inc. today?

Verastem, Inc. (VSTM) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Verastem, Inc.?

Yes, Indian Investors can invest in the Verastem, Inc. (VSTM) Share by opening an international trading account with Angel One.

How can I purchase Verastem, Inc. shares in India?

Purchasing Verastem, Inc. (VSTM) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Verastem, Inc. (VSTM) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Verastem, Inc.?

Yes, you can purchase fractional shares of Verastem, Inc. (VSTM) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Verastem, Inc.?

The market capitalization of Verastem, Inc. on January 1, 1970, is $0.

What documents are required to invest in Verastem, Inc. stocks?

In order to invest in Verastem, Inc. (VSTM) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.